Lumretuzumab Biosimilar - Research Grade

Human

ERBB3

>1mg/ml

IgG1 - kappa

CHO Cells

Patritumab Biosimilar - Research Grade (ICH5206), Duligotuzumab Biosimilar - Research Grade (ICH5493), Elgemtumab Biosimilar - Research Grade (ICH5513), Nezutatug Biosimilar - Research Grade (ICH5710), Seribantumab Biosimilar - Research Grade (ICH5854)

https://www.imgt.org/mAb-DB/

ICH3002

P21860

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of lumretuzumab, an anti-HER3 (ERBB3) antibody, supplied strictly for research use only. It is a human IgG1/kappa molecule engineered to recognise human ERBB3 and reproduce the binding behaviour of the originator antibody, but it is not the clinical drug and is not intended for human or veterinary use. As a research reagent it is useful for probing ERBB3 biology and antibody function: positive/isotype-matched controls in binding assays, benchmarking of ERBB3-directed binders, ligand-blocking and receptor-internalisation studies, and as a building block for ADC or bispecific development and ADCC characterisation. It supports both in-vitro cell-based work and preclinical in-vivo experimental systems where a defined, well-characterised anti-ERBB3 tool is needed. The material is offered at research grade with low endotoxin (typically <1 EU/mg, with an ultra-low <0.5 EU/mg option) and is available in bulk milligram-to-gram quantities to support assay development, reagent standardisation, and scale-dependent screening. Formats are unconjugated to give users flexibility for downstream labelling or conjugation. ERBB3 (HER3) is a member of the EGFR/HER receptor tyrosine kinase family. It contains an extracellular ligand-binding region, a single transmembrane domain, and a kinase-like domain that is catalytically impaired, so ERBB3 functions largely through heterodimerisation rather than as an active kinase on its own. Its principal ligands are the neuregulins (NRG1/heregulin), whose binding drives dimerisation with partners such as ERBB2 (HER2) and EGFR. The resulting heterodimers are potent activators of the PI3K-AKT survival and growth pathway, because ERBB3 carries multiple docking sites for the p85 subunit of PI3K. ERBB3 signalling contributes to normal epithelial and neural development, and aberrant ERBB3 activation is implicated in tumour proliferation, survival, and resistance to therapies targeting EGFR or HER2, making it a target of significant interest in oncology research.

Proto-oncogene-like protein c-ErbB-3, Tyrosine kinase-type cell surface receptor HER3, Receptor tyrosine-protein kinase erbB-3, HER3

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks